Clinical Practice Guideline: Immunotherapy for Inhalant Allergy
Fuente:
Wiley Open Access
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Publié: |
Wiley
2024
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1867002677130428416 |
|---|---|
| author | Richard K. Gurgel Fuad M. Baroody Cecelia C. Damask James “Whit” Mims Stacey L. Ishman Dole P. Baker Kevin J. Contrera Fariha S. Farid John A. Fornadley Donna D. Gardner LaKeisha R. Henry Jean Kim Joshua M. Levy Christine M. Reger Howard J. Ritz Robert J. Stachler Tulio A. Valdez Joe Reyes Nui Dhepyasuwan |
| author_facet | Richard K. Gurgel Fuad M. Baroody Cecelia C. Damask James “Whit” Mims Stacey L. Ishman Dole P. Baker Kevin J. Contrera Fariha S. Farid John A. Fornadley Donna D. Gardner LaKeisha R. Henry Jean Kim Joshua M. Levy Christine M. Reger Howard J. Ritz Robert J. Stachler Tulio A. Valdez Joe Reyes Nui Dhepyasuwan Richard K. Gurgel Fuad M. Baroody Cecelia C. Damask James “Whit” Mims Stacey L. Ishman Dole P. Baker Kevin J. Contrera Fariha S. Farid John A. Fornadley Donna D. Gardner LaKeisha R. Henry Jean Kim Joshua M. Levy Christine M. Reger Howard J. Ritz Robert J. Stachler Tulio A. Valdez Joe Reyes Nui Dhepyasuwan |
| collection | Wiley Open Access |
| contents | Clinical Practice Guideline: Immunotherapy for Inhalant Allergy Richard K. Gurgel Fuad M. Baroody Cecelia C. Damask James “Whit” Mims Stacey L. Ishman Dole P. Baker Kevin J. Contrera Fariha S. Farid John A. Fornadley Donna D. Gardner LaKeisha R. Henry Jean Kim Joshua M. Levy Christine M. Reger Howard J. Ritz Robert J. Stachler Tulio A. Valdez Joe Reyes Nui Dhepyasuwan Otolaryngology–Head and Neck Surgery AbstractObjectiveAllergen immunotherapy (AIT) is the therapeutic exposure to an allergen or allergens selected by clinical assessment and allergy testing to decrease allergic symptoms and induce immunologic tolerance. Inhalant AIT is administered to millions of patients for allergic rhinitis (AR) and allergic asthma (AA) and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT). Despite its widespread use, there is variability in the initiation and delivery of safe and effective immunotherapy, and there are opportunities for evidence‐based recommendations for improved patient care.PurposeThe purpose of this clinical practice guideline (CPG) is to identify quality improvement opportunities and provide clinicians trustworthy, evidence‐based recommendations regarding the management of inhaled allergies with immunotherapy. Specific goals of the guideline are to optimize patient care, promote safe and effective therapy, reduce unjustified variations in care, and reduce the risk of harm. The target patients for the guideline are any individuals aged 5 years and older with AR, with or without AA, who are either candidates for immunotherapy or treated with immunotherapy for their inhalant allergies. The target audience is all clinicians involved in the administration of immunotherapy. This guideline is intended to focus on evidence‐based quality improvement opportunities judged most important by the guideline development group (GDG). It is not intended to be a comprehensive, general guide regarding the management of inhaled allergies with immunotherapy. The statements in this guideline are not intended to limit or restrict care provided by clinicians based on their experience and assessment of individual patients.Action StatementsThe GDG made a strong recommendation that (Key Action Statement [KAS] 10) the clinician performing allergy skin testing or administering AIT must be able to diagnose and manage anaphylaxis. The GDG made recommendations for the following KASs: (KAS 1) Clinicians should offer or refer to a clinician who can offer immunotherapy for patients with AR with or without AA if their patients' symptoms are inadequately controlled with medical therapy, allergen avoidance, or both, or have a preference for immunomodulation. (KAS 2A) Clinicians should not initiate AIT for patients who are pregnant, have uncontrolled asthma, or are unable to tolerate injectable epinephrine. (KAS 3) Clinicians should evaluate the patient or refer the patient to a clinician who can evaluate for signs and symptoms of asthma before initiating AIT and for signs and symptoms of uncontrolled asthma before administering subsequent AIT. (KAS 4) Clinicians should educate patients who are immunotherapy candidates regarding the differences between SCIT and SLIT (aqueous and tablet) including risks, benefits, convenience, and costs. (KAS 5) Clinicians should educate patients about the potential benefits of AIT in (1) preventing new allergen sensitizations, (2) reducing the risk of developing AA, and (3) altering the natural history of the disease with continued benefit after discontinuation of therapy. (KAS 6) Clinicians who administer SLIT to patients with seasonal AR should offer pre‐ and co‐seasonal immunotherapy. (KAS 7) Clinicians prescribing AIT should limit treatment to only those clinically relevant allergens that correlate with the patient's history and are confirmed by testing. (KAS 9) Clinicians administering AIT should continue escalation or maintenance dosing when patients have local reactions (LRs) to AIT. (KAS 11) Clinicians should avoid repeat allergy testing as an assessment of the efficacy of ongoing AIT unless there is a change in environmental exposures or a loss of control of symptoms. (KAS 12) For patients who are experiencing symptomatic control from AIT, clinicians should treat for a minimum duration of 3 years, with ongoing treatment duration based on patient response to treatment. The GDG offered the following KASs as options: (KAS 2B) Clinicians may choose not to initiate AIT for patients who use concomitant beta‐blockers, have a history of anaphylaxis, have systemic immunosuppression, or have eosinophilic esophagitis (SLIT only). (KAS 8) Clinicians may treat polysensitized patients with a limited number of allergens. 10.1002/ohn.648 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1002/ohn.648 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_ohn_648 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Clinical Practice Guideline: Immunotherapy for Inhalant Allergy Richard K. Gurgel Fuad M. Baroody Cecelia C. Damask James “Whit” Mims Stacey L. Ishman Dole P. Baker Kevin J. Contrera Fariha S. Farid John A. Fornadley Donna D. Gardner LaKeisha R. Henry Jean Kim Joshua M. Levy Christine M. Reger Howard J. Ritz Robert J. Stachler Tulio A. Valdez Joe Reyes Nui Dhepyasuwan Otolaryngology–Head and Neck Surgery Clinical Practice Guideline: Immunotherapy for Inhalant Allergy Richard K. Gurgel Fuad M. Baroody Cecelia C. Damask James “Whit” Mims Stacey L. Ishman Dole P. Baker Kevin J. Contrera Fariha S. Farid John A. Fornadley Donna D. Gardner LaKeisha R. Henry Jean Kim Joshua M. Levy Christine M. Reger Howard J. Ritz Robert J. Stachler Tulio A. Valdez Joe Reyes Nui Dhepyasuwan Otolaryngology–Head and Neck Surgery AbstractObjectiveAllergen immunotherapy (AIT) is the therapeutic exposure to an allergen or allergens selected by clinical assessment and allergy testing to decrease allergic symptoms and induce immunologic tolerance. Inhalant AIT is administered to millions of patients for allergic rhinitis (AR) and allergic asthma (AA) and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT). Despite its widespread use, there is variability in the initiation and delivery of safe and effective immunotherapy, and there are opportunities for evidence‐based recommendations for improved patient care.PurposeThe purpose of this clinical practice guideline (CPG) is to identify quality improvement opportunities and provide clinicians trustworthy, evidence‐based recommendations regarding the management of inhaled allergies with immunotherapy. Specific goals of the guideline are to optimize patient care, promote safe and effective therapy, reduce unjustified variations in care, and reduce the risk of harm. The target patients for the guideline are any individuals aged 5 years and older with AR, with or without AA, who are either candidates for immunotherapy or treated with immunotherapy for their inhalant allergies. The target audience is all clinicians involved in the administration of immunotherapy. This guideline is intended to focus on evidence‐based quality improvement opportunities judged most important by the guideline development group (GDG). It is not intended to be a comprehensive, general guide regarding the management of inhaled allergies with immunotherapy. The statements in this guideline are not intended to limit or restrict care provided by clinicians based on their experience and assessment of individual patients.Action StatementsThe GDG made a strong recommendation that (Key Action Statement [KAS] 10) the clinician performing allergy skin testing or administering AIT must be able to diagnose and manage anaphylaxis. The GDG made recommendations for the following KASs: (KAS 1) Clinicians should offer or refer to a clinician who can offer immunotherapy for patients with AR with or without AA if their patients' symptoms are inadequately controlled with medical therapy, allergen avoidance, or both, or have a preference for immunomodulation. (KAS 2A) Clinicians should not initiate AIT for patients who are pregnant, have uncontrolled asthma, or are unable to tolerate injectable epinephrine. (KAS 3) Clinicians should evaluate the patient or refer the patient to a clinician who can evaluate for signs and symptoms of asthma before initiating AIT and for signs and symptoms of uncontrolled asthma before administering subsequent AIT. (KAS 4) Clinicians should educate patients who are immunotherapy candidates regarding the differences between SCIT and SLIT (aqueous and tablet) including risks, benefits, convenience, and costs. (KAS 5) Clinicians should educate patients about the potential benefits of AIT in (1) preventing new allergen sensitizations, (2) reducing the risk of developing AA, and (3) altering the natural history of the disease with continued benefit after discontinuation of therapy. (KAS 6) Clinicians who administer SLIT to patients with seasonal AR should offer pre‐ and co‐seasonal immunotherapy. (KAS 7) Clinicians prescribing AIT should limit treatment to only those clinically relevant allergens that correlate with the patient's history and are confirmed by testing. (KAS 9) Clinicians administering AIT should continue escalation or maintenance dosing when patients have local reactions (LRs) to AIT. (KAS 11) Clinicians should avoid repeat allergy testing as an assessment of the efficacy of ongoing AIT unless there is a change in environmental exposures or a loss of control of symptoms. (KAS 12) For patients who are experiencing symptomatic control from AIT, clinicians should treat for a minimum duration of 3 years, with ongoing treatment duration based on patient response to treatment. The GDG offered the following KASs as options: (KAS 2B) Clinicians may choose not to initiate AIT for patients who use concomitant beta‐blockers, have a history of anaphylaxis, have systemic immunosuppression, or have eosinophilic esophagitis (SLIT only). (KAS 8) Clinicians may treat polysensitized patients with a limited number of allergens. 10.1002/ohn.648 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Clinical Practice Guideline: Immunotherapy for Inhalant Allergy |
| topic | Otolaryngology–Head and Neck Surgery |
| url | https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/10.1002/ohn.648 |